"Diarylquinolines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of quinoline compounds defined by the presence of two aromatic ring structures which are attached via a side chain to carbon 3 of the qunolinyl structure. The two aromatic moieties are typically NAPTHALENE and BENZENE. Several compounds in this class are used as ANTITUBERCULAR AGENTS.
| Descriptor ID |
D064687
|
| MeSH Number(s) |
D03.633.100.810.087
|
| Concept/Terms |
Diarylquinolines- Diarylquinolines
- Diarylquinoline Derivatives
- Derivatives, Diarylquinoline
- Diaryl Quinoline Derivatives
- Derivatives, Diaryl Quinoline
- Quinoline Derivatives, Diaryl
|
Below are MeSH descriptors whose meaning is more general than "Diarylquinolines".
Below are MeSH descriptors whose meaning is more specific than "Diarylquinolines".
This graph shows the total number of publications written about "Diarylquinolines" by people in this website by year, and whether "Diarylquinolines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 1 | 1 | 2 |
| 2017 | 2 | 0 | 2 |
| 2018 | 0 | 3 | 3 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 2 | 3 |
| 2021 | 1 | 1 | 2 |
| 2022 | 0 | 1 | 1 |
| 2023 | 1 | 1 | 2 |
| 2024 | 3 | 1 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Diarylquinolines" by people in Profiles.
-
Bedaquiline: what might the future hold? Lancet Microbe. 2024 Dec; 5(12):100909.
-
Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe: author's response. Clin Microbiol Infect. 2024 Sep; 30(9):1207-1208.
-
Treatment of MDR, Pre-XDR, XDR, and Rifampicin-Resistant Tuberculosis or in Case of Intolerance to at Least Rifampicin in Austria, Germany, and Switzerland. Respiration. 2024; 103(9):593-600.
-
Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe. Clin Microbiol Infect. 2024 Sep; 30(9):1197.e1-1197.e4.
-
Emerging bedaquiline-resistant tuberculosis. Lancet Microbe. 2023 12; 4(12):e964-e965.
-
Regimens for Drug-Resistant Tuberculosis. N Engl J Med. 2023 01 12; 388(2):190.
-
Emergence of bedaquiline resistance in a high tuberculosis burden country. Eur Respir J. 2022 03; 59(3).
-
Evidence-based Definition for Extensively Drug-Resistant Tuberculosis. Am J Respir Crit Care Med. 2021 09 15; 204(6):713-722.
-
Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country. Eur Respir J. 2021 06; 57(6).
-
Bedaquiline and delamanid result in low rates of unfavourable outcomes among TB patients in Eswatini. Int J Tuberc Lung Dis. 2020 10 01; 24(10):1095-1102.